Full-Time

Cardiology Regional Medical Lead

Confirmed live in the last 24 hours

HeartFlow

HeartFlow

501-1,000 employees

Non-invasive cardiac testing for heart disease

Healthcare

Compensation Overview

$180k - $220kAnnually

+ Cash Bonus + Stock Options

Senior

Cleveland, OH, USA + 2 more

More locations: Chicago, IL, USA | Minneapolis, MN, USA

Significant travel (~50% of time) required.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • Advanced clinical or scientific degree (PharmD, PhD, or MD/DO, MS, PA, ARNP) preferred
  • Minimum of 5 years of Cardiovascular experience, experience in lipid management ideal
  • Experience in pharma, biotech and or/medical devices, ideally as a medical science liaison (MSL)
  • Significant direct experience communicating complex scientific information in a manner that meets the needs of external healthcare practitioners and internally at all levels of the organization
  • Advanced presentation and computer skills with expertise in literature identification and evaluation.
Responsibilities
  • Establish and foster professional relationships with national and regional Key Opinion Leaders (KOLs) in lipid management and preventive cardiology and with internal business partners
  • Support the identification and training of educational faculty
  • Serve as a key HeartFlow scientific resource in the field, supporting HCP education including advanced data and case reviews
  • Gather feedback and insights from KOLs and physician advisors to better inform HeartFlow’s overall strategic direction
  • Identify and support regional education opportunities
  • In collaboration with the Clinical team at HeartFlow, facilitate initial discussions, intake, and evaluation of physician-initiated research proposals, including ensuring timely communication between requestor and company
  • Understand and effectively communicate current scientific knowledge, maintaining expertise through keeping up to date with publications and attendance of national and local congresses
  • Monitor major meetings for abstract deadlines and work with investigators of HeartFlow sponsored research to drive podium presence in support of corporate communication strategies and plan
  • Support field and internal training needs as a clinical expert

HeartFlow provides a non-invasive cardiac test that helps visualize a patient's coronary arteries in detail. This technology allows physicians to diagnose and treat heart disease more effectively without the need for invasive procedures, which reduces risks for patients and costs for healthcare providers. HeartFlow's main products include the HeartFlow Analysis, which encompasses various analyses like FFRCT, RoadMap, Plaque, and HeartFlow Planner. These products have received FDA clearance and are available in the United States, the United Kingdom, Japan, and Canada. Unlike many competitors, HeartFlow focuses on providing a safer and more efficient diagnostic method for cardiovascular care. The company's goal is to enhance the quality of heart disease treatment through its proprietary technology, ultimately improving patient outcomes.

Company Stage

Series F

Total Funding

$858.5M

Headquarters

Redwood City, California

Founded

2010

Growth & Insights
Headcount

6 month growth

4%

1 year growth

15%

2 year growth

18%
Simplify Jobs

Simplify's Take

What believers are saying

  • HeartFlow closed a $215 million Series F funding round to expand its product portfolio.
  • The global market for non-invasive cardiac imaging is projected to grow significantly.
  • HeartFlow's AI-enabled solutions align with the trend towards value-based healthcare.

What critics are saying

  • Increased competition from emerging AI-driven cardiovascular diagnostic companies threatens HeartFlow's market share.
  • Reliance on AI models poses a risk of algorithmic bias in HeartFlow's diagnostics.
  • Integration of HeartFlow's technology may face resistance due to complexity and cost.

What makes HeartFlow unique

  • HeartFlow offers the only combined anatomy, physiology, and plaque analysis for heart disease.
  • HeartFlow's AI-driven FFRCT Analysis provides a non-invasive alternative to traditional cardiac tests.
  • HeartFlow's technology is FDA-cleared and commercially available in major global markets.

Help us improve and share your feedback! Did you find this helpful?